Resources Archive - WuXi Biology

Novel E3 Ligase to Support Targeted Protein Degradation

Targeted protein degradation (TPD) continues to expand the possibilities for next-generation therapeutics, and identifying novel E3 ligases remains an important...

Mechanistic Profiling of ADC-resistant Cancer Cell Lines

Antibody-drug conjugates (ADCs) have emerged as an important modality in targeted cancer therapy development. However, acquired resistance continues to limit...

Unveiling Mechanisms of MRTX1133 Resistance

Recent years have seen major advances in KRAS G12D-targeted therapeutics. However, acquired drug resistance remains a significant clinical challenge, with...

Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

Biophysical Methods for Rapid Screening and Hit Validation

At DDC 2026, WuXi AppTec presented a poster showcasing our integrated discovery platform designed to accelerate the identification and validation...

Spectral Shift for Ultra-High-Throughput Binding Assays

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...

Targeted In Vitro Pharmacology for GIPR/GLP-1R/GCGR

Current weight-loss therapies primarily act on the gut–brain axis, often using incretin-based approaches such as GIP, GLP-1, and glucagon receptor...

DEL and Display Technologies Empower Discovery of Peptide Drugs

In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...

Knowledge Library